DDX11L17

Across TCGA pan-cancer cohorts, DDX11L17 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of DDX11L17’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where DDX11L17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DDX11L17 is over-expressed in tumor, although a few such as KICH and KIRC show the opposite, repressed pattern.

LIHC, KICH, and KIRC are the cancer types where DDX11L17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DDX11L17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.067	.002	5	view →
KICH	All	All	−0.204	.021	3	view →
KIRC	All	All	−0.083	.028	3	view →
LUSC	Female	III,IV	+0.265	.004	1	view →
HNSC	All	II,III,IV	+0.099	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

DDX11L17–LIHC

Open the LIHC breakdown →